Navigation Links
Artecoll


Artecoll, used in cosmetic plastic surgery as permanent soft tissue filler, is injected under the skin to plump up wrinkles and reduce folds of skin associated with aging such as the nasolabial fold which runs from the corner of the nose to the edges of the mouth. Now produced for Americans in San Diego, California, by Artes Medical, Inc, Artecoll has been used in Europe for many years. It was approved by the U.S. FDA in December, 2006, to treat nasolabial folds with the added condition that a five-year follow up study of patients using Artecoll must be done.

Contents

Composition

Artecoll is mostly collagen, one of the most abundant substances in all mammals. The thinning of collagen in human faces is responsible for aging, wrinkles and lines on the face.[1]

Artecoll consists of 25 percent microscopic Plexiglas plastic beads made of a substance known as polymethylmethacrylate suspended in a solution of 75 percent bovine collagen. The microspheres are 32–40 micrometers in diameter (500 micrometers could fit in the period at the end of this sentence).

Potential risks and side effects

Some researchers have found that large lumps under the skin known as granulomas developed after Artecoll injections. The lumps are a reaction to the injections and can be difficult for doctors to treat.[2]

U.S. Food and Drug Administration approval

Before Artecoll was approved by the U.S. FDA, it was studied in 251 subjects at eight medical centers in the United States. The subjects received Artecoll injections in 1334 wrinkles of the glabella, the heavy wrinkles between the eyebrows, in the corner-of-the-mouth lines, in upper lips and in the nasolabial folds. A similar group of patients received injections of ordinary collagen (with the trade name Zyplast™) in the same places in their faces.

Researchers then studied the patients' improved appearance and the reactions of research subjects to the injections. At the six-month follow up, the researchers found the Artecoll group showed 86.7 percent better augmentation of loose skin than the group which received only collagen. Adverse reactions to collagen and to Artecoll among both groups of patients was reported as about equal.[3]

References

  1. ^ Cohen SR, Homes RE. Artecoll: A long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg. 2004; 114:964-976
  2. ^ Sidwell, R.U.; Mcl Johnson, N; Francis, N. +; Bunker, C.B. Cutaneous sarcoidal granulomas developing after Artecoll® facial cosmetic filler in a patients with newly diagnosed system sarcoidosis. Clinical & Experimental Dermatology, 31(2):208-211. March 2006.
  3. ^ Rullan, Peter Paul M.D. Soft Tissue Augmentation using Artecoll: A Personal Experience. Facial Plastic Surgery. 20(2):111-116, May 2004.

External links


'"/>


(Date:9/30/2014)... in 2003 to slow the spiraling costs of drugs ... patients has had no meaningful impact on cancer chemotherapy ... Journal of Clinical Oncology published online today. ... treat colorectal and lung cancers, and did not find ... following the implementation of the recent Medicare law in ...
(Date:9/30/2014)... York, NY (PRWEB) September 30, 2014 ... falling demand have hampered growth in the Bread ... diets have caused consumers to moderate their consumption ... consumer preferences for premium varieties shrunk the market ... products. Successful operators proactively responded by introducing more ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2
... BFRM ) today announced its financial results for the ... of fiscal,year 2008. Net sales were $18.6 million for the ... the quarter ended December 31, 2006,an increase of $6.8 million ... ended December 31, 2007 as compared to $2.7 million for ...
... Mass., Jan. 31 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... presentation,at the 2008 Merrill Lynch Global Pharmaceutical, ... live and may be accessed by visiting ... http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ...
... Jan. 31 In hopes of gaining a better,grasp ... focusing more on sales training tools and techniques to,provide ... reps,the first year of training and preparation is critical ... rep of approximately $10,500 in,the first year of employment, ...
... January 31, 2008 All candidates running for office in ... care system for the United States that is second to ... its annual report on The State of the Nations Health ... designed to gain candidate commitments to support a series of ...
... KENILWORTH, N.J., Jan. 31 Schering-Plough,Corporation (NYSE: ... antifungal agent NOXAFIL(R),(posaconazole) Oral Suspension received an ... invasive Aspergillus infections in certain,high- risk patients ... Guidelines of the Infectious Diseases Society of ...
... ovarian failure, researchers report , , THURSDAY, Jan. 31 (HealthDay ... that prompts early menopause and might account for some ... that,s known for suppressing tumor growth -- apparently also ... quickly. When researchers deleted the PTEN gene in mice, ...
Cached Medicine News:Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 2Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 3Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 4Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 5Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 6Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 7Health News:2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:Achieving a US health care system 'second to none' 2Health News:Achieving a US health care system 'second to none' 3Health News:Achieving a US health care system 'second to none' 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 2Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 5Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 6Health News:Study Spots Gene That Plays Role in Infertility 2
Other medicine definitionOther Tags